Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Multiple Oral Doses of AK3280 on Renal Function in Healthy Subjects

Next Previous
Trial Profile

A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Multiple Oral Doses of AK3280 on Renal Function in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AK 3280 (Primary)
  • Indications Interstitial lung diseases
  • Focus Pharmacodynamics
  • Sponsors Ark Biosciences

Most Recent Events

  • 08 Jun 2021 Status changed from recruiting to completed.
  • 08 Jan 2020 According to an Ark Biosciences media release, updates from this study will be presented at the JP Morgan Healthcare Conference on January 15th 2020.
  • 01 Oct 2019 Planned initiation date changed from 31 Aug 2019 to 7 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top